Sichuan Biokin Launches Phase III Trial of T‑Bren for HER2‑Mutant NSCLC
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today the enrollment of the first patient...
Anhui Anke Announces HuA21 Success in HER2‑Positive Gastric Cancer
Anhui Anke Biotechnology (Group) Co., Ltd. today released interim results from its Phase Ib/II study of...
Novartis Announces First‑In‑Class Phase III Data for Lutetium‑177 Vipivotide Tetraxetan in PSMA‑Positive Metastatic Hormone‑Sensitive Prostate Cancer
Novartis (NYSE: NVS) today disclosed the first data from its Phase III PSMAddition trial of lutetium‑177...
Boston Scientific Announces Nalu Medical Acquisition to Expand Chronic‑Pain Portfolio
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement...
Accord Plasma Completes Acquisition of Prothya Biosolutions, Expanding European Plasma‑Derived Medicinal Product (PDMP) Capabilities
Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed...
Changchun High‑Tech Secures NMPA Approval for GenSci139 Bispecific ADC in Advanced Solid Tumors
Changchun High‑Tech (SHE: 000661) announced today that its wholly‑owned subsidiary, GenSci (GeneScience Pharmaceutical), has received...
Salubris Shares Promising JK06 ADC Results from ESMO 2025 Clinical Presentation
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced today that its U.S. subsidiary, Salubris Biotherapeutics,...
Advaccine Biotechnology Announces Private Placement of Up to 2.2 Million Shares to Raise RMB 300 Million for Microneedle & Vaccine Development
Advaccine Biotechnology (NEEQ: 874055) today disclosed a private placement offering of no more than 2,203,200 shares...
Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR‑Mutated NSCLC
Summit Therapeutics, the former China partner of Akeso Inc. (HKG: 9926), announced today that it...
Samsung Bioepis Announces Global ADC Collaboration with Phrontline Biopharma to Advance TJ108
Samsung Bioepis Co., Ltd. today announced a strategic, worldwide partnership with Phrontline Biopharma to jointly develop,...
Shanghai Henlius Biotech Secures FDA Orphan Drug Designation for HLX43 in Thymic Epithelial Tumors
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced today that the U.S. Food and Drug Administration...
CARsgen Announces Promising Phase Ib Results for Satricabtagene Autoleucel Injection in Post‑Surgery Pancreatic Cancer
CARsgen Therapeutics Holdings Limited (HKG: 2171) today disclosed interim data from the Phase Ib registrational study...
CSPC Pharmaceutical Secures Breakthrough Therapy Designation for JSKN003 in HER2‑Positive Colorectal Cancer
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that JSKN003, a HER2‑bi‑epitope targeted antibody‑drug conjugate (ADC)...
Akeso Announces Landmark Phase III Results for IVONESCIMAB in First‑Line Sq‑NSCLC
Akeso Inc. (HKG: 9926) today disclosed the results of its global first‑in‑class bispecific antibody ivonescimab...
Wuhan YZY Biopharma Announces Interim Phase II Results for M701 in Malignant Pleural Effusion
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) today disclosed interim data from its Phase II clinical...
China Isotope & Radiation Corp. Signs MoU With Brazil’s CNEN for Long‑Term Isotope Supply
China Isotope & Radiation Corporation (HKG: 1763) announced today that it has signed a Memorandum...
Wuhan Healthgen Announces STAR Market IPO of ORYZOGEN Shares
Wuhan Healthgen Biotechnology Corp. (SHA: 688765) today announced that the Shanghai Stock Exchange has approved...
Alphamab Oncology Announces Interim Phase III Results for Anbenitamab in HER2‑Positive Gastric Cancer
Alphamab Oncology (HKG: 9966) today disclosed the first interim data from its Phase III study evaluating...
Fosun Kairos Secures Series A Financing to Propel Cell‑Therapy Expansion
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the Shenzhen Biopharmaceutical Industry Fund...
Multitude Therapeutics Announces Early‑Stage Efficacy Signals for AMT‑116, a First‑In‑Class CD44v9‑Targeting ADC
Multitude Therapeutics, Inc. today released preliminary data from its ongoing Phase I/II, open‑label, multicenter, dose‑escalation and...